Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
| Revenue (Most Recent Fiscal Year) | $0.08M |
| Net Income (Most Recent Fiscal Year) | $-21.75M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.75 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -38.26% |
| Return on Assets (Trailing 12 Months) | -35.71% |
| Current Ratio (Most Recent Fiscal Quarter) | 14.80 |
| Quick Ratio (Most Recent Fiscal Quarter) | 14.80 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.81 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.24 |
| Earnings per Share (Most Recent Fiscal Year) | $-6.00 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 25.60M |
| Free Float | 25.27M |
| Market Capitalization | $399.11M |
| Average Volume (Last 20 Days) | 0.04M |
| Beta (Past 60 Months) | 0.34 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 52.19% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |